Preliminary circulating tumour cell (CTC) analysis in phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel treatment (SOGUG-CABASEM trial).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e16034-e16034
Author(s):  
Luis Leon Mateos ◽  
Laura Muinelo ◽  
Begoña Perez-Valderrama ◽  
Begoña Mellado ◽  
María José Juan Fita ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Tumour Cell ◽  
Phase Ii Study ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Docetaxel Treatment ◽  
Circulating Tumour Cell

Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy

The Prostate ◽  
2011 ◽  
Vol 72 (8) ◽  
pp. 834-845 ◽  
Author(s):  
Masanori Noguchi ◽  
Fukuko Moriya ◽  
Shigetaka Suekane ◽  
Kei Matsuoka ◽  
Gaku Arai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Castration Resistant Prostate Cancer ◽  
Peptide Vaccination ◽  
Castration Resistant

Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study

2014 ◽  
Vol 12 (1) ◽  
pp. 27-32 ◽  
Author(s):  
Chadi Nabhan ◽  
Anand Patel ◽  
Dana Villines ◽  
Kathy Tolzien ◽  
Susan K. Kelby ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant
Sign in / Sign up

Export Citation Format

Share Document